BioTime’s Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTime’s subsidiary ReCyte Therapeutics, Inc. will provide and update on the development of reprogramming technologies and the generation of patient-specific vascular endothelial cells with essentially 100% purity using proprietary ACTCellerateTM technology.